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and Health Zone. CONCLUSIONS: Age-adjusted death rates of unintentional fatal
poisonings increased for Kansas City, Missouri, from 1999 to 2008. Sex, age, annual
income, and Health Zone, were risk factors for unintentional fatal poisonings.
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OBJECTIVES: Emergency Department [ED] overcrowding is a national problem.
This study evaluates the effect of a provider/nurse triage model (Rapid Evaluation
Unit, REU) designed to improve the efficiency of the ED on ED patient volume and
ambulance diversionhours.METHODS:Data ondaily patient counts [inpatient, ED]
and ambulance diversion hours for a single hospital in Baltimore were used to
evaluate the impact of REU on hospital performance. Data covered 2008, the year
before the REU was implemented, and 2009 during which the REU was imple-
mented incrementally. The REU was operating on Monday-Wednesday from Jan-
uary 1st through March 31st, and then Monday through Friday from April 1st
through December 31st. Regression models were estimated for the daily counts for
admissions, ED visits and ambulance diversion days controlling for time trend
effects, day of the week and month of the year. A spline functional form was used
to test the effects of the REU on pre-2009 time trends and to improve model fit.
Models were adjusted for autocorrelation and heteroskedasticity as needed.
RESULTS: The REU significantly increased ED patient visit counts by 5.5 visits per
day [p0.01] without increasing the number of hours the hospital was diverting
ambulances due to over crowding [0.83 hours per day, p0.05]. For ED visits, all
months exhibited significantly higher daily ED visit counts than inDecember, rang-
ing from 9 to 28 visits per day. The early work week [Monday-Wednesday] also
exhibited significantly higher rates of ED visits than Saturday [range: 5-12 visits per
day].CONCLUSIONS:The REUwas effective at increasing ED visitswithout increas-
ing ambulance diversion hours. We theorize that this may be due to a reduction in
the time spent by patients waiting for treatment.
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OBJECTIVES:Medication reconciliation is the process of obtaining andmaintaining
a complete and accurate list of the current medication therapy of a patient across
health care setting. The combination of recorded and reported (assessed through
patient counseling) medication use may increase the accuracy of medication rec-
onciliation process. The objective of this study is to prevent drug-related problems
and evaluate the effect of pharmacist-conducted medication reconciliation with
patient counseling at hospital admission.METHODS: Patients who were admitted
to Internal Medicine in local hospital, with age over 65 years, more than two co-
morbidities and receiving more than three regular medications were recruited.
Patients with cancer, admitted to the ICU, discharged within 48 hours, or unable to
communicate were excluded. Then, these patients were interviewed by pharma-
cists within 48 hours after admission. The unintentional discrepancies were dis-
cussed with the physicians and drug therapy would be adjusted accordingly. The
primary outcome of this study included the rate of unintentional discrepancies
identified by pharmacists before and after patient counseling and the rate of un-
reconciled medications resolved by pharmacists. RESULTS: Forty-nine patients
were recruited in this study and 129 unreconciledmedicationswere found between
October 17 and November 18, 2010. The most common type of discrepancies was
omissions with rate of 58.7%. On the other hand, the rate of unintentional discrep-
ancies identified by pharmacist which may cause harm increased from 6.6% to
12.4% after patients counseling and 81.3% of drug-related problem was resolved
after pharmacist intervention. Additionally, allergy history was established in
16.3% of patients. CONCLUSIONS: Pharmacist-conducted medication reconcilia-
tion with patient counseling improved drug therapy and completeness and accu-
racy of allergy history. However, this studywas only undertaken in patients admit-
ted to Internal Medicine during one month. Implementation of medication
reconciliationwith patient counseling to further patients, such as surgical patients
may be considered.
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OBJECTIVES: The aim of the present analysis was to identify what was the influ-
ence of prices and the corresponding low cost-effectiveness estimates of the ap-
praised orphan drugs on AHTAPol recommendations. The main task of AHTAPol,
established in 2005, is to assess and appraise all medical technologies and services
claiming publicmoney founding. Pharmacoeconomic evaluations of new therapies
are required for all reimbursement decisions and orphan drugmanufacturers can-
not be exempted from providing a full pharmacoeconomic or HTA reports. Recom-
mendations issued by AHTAPol have been based onManufacturer‘s submission,
additional officially published data, experts opinions and Polish public payer
(National Health Fund) evaluation.METHODS: All recommendations issued by the
AHTAPol until the end of 2010 were reviewed and analyzed from the official Web site
ofAHTAPol. Theorphandrugs recommendationswere identifiedand categorized into
types of recommendations (positive or negative) and reasoned. RESULTS:Among 286
AHTAPol decisions studied, 26 (9%) applied to orphan drugs. AHTAPol gave positive
recommendations for reimbursement to 19 of 26 of orphan drug submissions (73%). 7
(27%) were not approved and received negative recommendations. Only in one case
cost-effectiveness estimates and the corresponding high priceswere emphasized as a
main reason of negative recommendations. In 1 case the reason was connected
with drug safety issues, while in 5 cases with insufficient evidence of efficacy.
CONCLUSIONS:Thecost-effectiveness issues of theappraisedorphandrugswerenot
important argument in negative recommendations of the AHTAPol. In fact the insuf-
ficient evidence of clinical efficacy were the most important and therefore prevailing
argument for issuing negative opinions of AHTAPol recommendations.
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OBJECTIVES: Indirect and Mixed Treatment Comparisons (ITC/MTC) can provide
valuable information for decision-makers, especially when direct comparisons be-
tween medicines are unavailable. The objective of this study is to investigate the
methods and impact of ITC and MTC submitted by manufacturers on the NICE
committee’s appraisal of pharmaceuticals. METHODS: A search of the NICE web-
site was conducted for manufacturers’ submissions that reported to contain either
an ITC orMTC since 2006. Datawere extracted and analysed for the type of network
meta-analysis, number of trials, head-to-head trial evidence available, disease
area, treatment comparisons, study selection justification, sensitivity analysis of
trial selection and outcome(s). The impact was assessed by analysing information
on Evidence Review Group (ERG) review of evidence synthesis, Appraisal commit-
tee’s comments and final decision. RESULTS: The search identified 24 submissions
that included either a MTC or ITC. The issues most frequently raised by the ERG
were lack of reporting of trial characteristics, description of methods and quality
assessment of all trials included. The most frequent validity concerns were both
clinical and statistical heterogeneity between trials, inappropriate methods of
analysis, exclusion of relevant trials and sparse numbers of trials in the network.
The committee considered all evidence and reported the analysis to be plausible on
one occasion, stated concernswith the validity in 18 appraisals and did not directly
comment on 5 occasions. Fifty eight percent of appraisals including an MTC or ITC
resulted in a restricted decision. CONCLUSIONS: ITC and MTC analysis has pro-
vided additional useful information for NICE appraisals but there has been wide
variation in the reporting and validity of analysis performed. Reimbursement
agencies should establish guidelines for the conduct of ITC andMTC to reduce this
variation. The emerging ISPOR Good Research Practice guide on indirect treatment
comparisons will provide a basis for these.
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OBJECTIVES: The objective was to understand the extent of the insurance-loss
problem in the United States over a four-year period (2004-2007) by (1) determining
the number (and proportion) of individuals who experienced loss in insurance
coverage and (2) for those who experienced gaps in coverage, determining the
average length of those periods of time when they were without coverage.
METHODS: This study was a retrospective, longitudinal data analysis using
monthly data from the 2004-05, 2005-06, and 2006-07 panels of the Medical Expen-
diture Panel Survey (MEPS). Individuals were categorized on the basis of continuity
of insurance coverage: a cohort of continuously insured individuals; a cohort of
continuously uninsured people; and a cohort of people who experienced gaps
(from one to 23 months) in coverage. The number and percent of individuals who
were in each group for each panel were calculated. A chi-square test was used to
determine if therewere differences in the distribution of health insurance patterns
between the panels, and ANOVA was used to determine if there were differences
between the average gap length over the years. RESULTS: Pooling across the three
panels, there were 157,641,235 (17.37%) individuals who experienced gaps in insur-
ance coverage, 82,826,100 (9.12%)whowere continuously uninsured for 24months,
and 616,864,391 (67.95%) who had continuous coverage over a two-year period. The
proportion of continuously uninsured rose from 8.73% in 2004-05 to 9.23% in 2006-
07. The average gap length was 8.56, 8.44, and 8.54months in 2004-05, 2005-06, and
2006-07 respectively. There were no significant differences across the panels in
either the distribution of insurance coverage patterns or between the average gap
lengths. CONCLUSIONS: Patterns in health insurance coverage have remained sta-
ble over the past several years. Examination of changing patterns of insurance
coverage will be important as health reform is introduced between now and 2014.
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OBJECTIVES:TheNational List of Health Services (NLHS) in Israel has been updated
annually since 1999 but results from economic evaluations (EE) were not used to
support coverage decisions. We explored the potential availability of EE results to
the committee responsible for updating the NLHS at the times of coverage deci-
sions and whether availability and use of these data could have altered these
decisions. METHODS: We used the Tufts Medical Center Cost-Effectiveness Anal-
ysis Registry (http://www.cearegistry.org) to search for relevant cost/QALY EE for
all drugs and their relevant indications added to the NLHS from 1999 through 2008.
For each pair of drug and cost/QALY publication we recorded the publication date,
the intervention(s) and comparator(s) considered and the incremental cost-effec-
tiveness ratio (ICER) to determine value for money. Based on available ICERs we
qualitatively classified each coverage decision into one of three categories: 1)The
coverage decision can be justified on EE grounds (EE suggest the drug is either
dominant/cost-saving or provides good value for money); 2)The coverage decision
cannot be justified on EE grounds; 3)The evidence from EE is mixed and we could
not determine whether the coverage decision can be justified or not. RESULTS:
Relevant cost/QALY analyses were found for 181(40%) of 451 drugs included in the
updates of the NLHS of which only 71 (16%) of drugs had relevant EE prior to the
coverage decision. Based on the evidence gathered from EE prior to and following
the coverage decision, we suggest that decisions were correct in 56% of the cases,
incorrect in 17% and ambiguous in 27%. CONCLUSIONS: The use of EE to support
coverage decisions could have altered decisions in a sizable proportion of drugs
added to the NLHS in Israel. Avoiding the use of results from EE to support public
funding of drugs may lead to a non-optimal use of scarce healthcare resources.
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OBJECTIVES: Orphan drug (OD) legislation has been highly successful in incentiv-
ising pharmaceutical companies to invest in developing medicines for previously-
ignored rare diseases. Since 2005, a third of all new drug approvals in the US have
been ODs, and worldwide the market is forecast to grow at a CAGR of 6%, reaching
$112bn in 2014. Although these products still only account for 2-3% of total drug
budgets in the US and EU, their burgeoning number is placing increased pressure
on funding. This poster aims to explore how payers in the US and EU are respond-
ing to these financial demands. METHODS: We reviewed all ODs approved in the
US and EU since 1st January 2000 and, for each, calculated the average cost per
patient per year, based on public prices in the US and 5EU. We also reviewed
published payer assessments of these products, and all government proposals
regarding OD policies since 2005. RESULTS: Since 2007, there has been an obvious
drop in prices secured for novel ODs. In the EU alone, the average cost per patient
per year for products approved in 2008 to 2010 (€34,890) is 73% lower than for those
approved in 2000 to 2007 (€129,228). Furthermore, our analysis suggests payers are
adopting a more discerning approach to the way they evaluate orphan drugs, es-
pecially those perceived to be exploiting the original intent of the legislation. For
example, Germany’s recent healthcare reforms highlighted plans to target ODs
that fail to demonstrate meaningful patient benefits, such as survival, and all ODs
exceeding annual sales of €50m will have to submit a cost-benefit analysis.
CONCLUSIONS: Payers are clamping down on “opportunistic” ODs and only those
with a robust body of evidence supporting both the clinical and economic argu-
ments for their use will secure favourable pricing and market access.
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OBJECTIVES: HTA agencies worldwide have varying processes that allow consul-
tation with stakeholders during decision-making. The objective of this study is to
determine the impact of the National Institute for Health and Clinical Excellence
(NICE) Single Technology Appraisal (STA) consultation stage on reimbursement
decisions of pharmaceuticals. METHODS: Documentation was accessed from the
NICE website for all STA’s conducted between 2006 and August 2010. Details of the
first Appraisal Consultation Document (ACD) draft decision, subsequent ACDs,
Final Appraisal Determination (FAD) and final guidance decision were extracted.
The decisions were categorised with respect to the licensed indication (recom-
mended, restricted, not recommended, only in research). Details of the further
analysis and evidence submitted by the manufacturer as a result of consultation
were extracted. These data were analysed for the different stages of
decision-making. RESULTS: The website search identified 55 NICE appraisals of
which over fifty percent were for cancer medicines. Final decisions (draft first
provisional decision) included 36% (13%) recommended, 36% (20%) restricted deci-
sion, 16% (56%) not recommendeddecision and 11% (11%) terminated decision. One
appraisal contained only in research recommendations in addition for use in rou-
tine practice. An ACDwas produced in 42 appraisals, followed by themanufacturer
providing further economic analysis in 26 appraisals, a patient access scheme in 5
appraisals and new clinical evidence in 2 appraisals. Types of further economic
analysis provided by the manufacturer were for other treatments/strategies; dif-
ferent modelling assumptions; alternative survival distributions; further sensitiv-
ity analysis; and other. CONCLUSIONS: NICE’s iterative consultation process al-
lows consideration of evidence and wide consultation with stakeholders. This
results in evidence that is more appropriate for the evaluation of pharmaceutical’s
and partly explains the higher recommendation rate when compared with similar
international reimbursement agencies. There is a need for further research to un-
derstand the impact of the different processes employed across countries’ deci-
sion-making.
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OBJECTIVES: Comparative effectiveness (US) and value-based pricing (VBP) (UK)
are anticipated to bring changes froma ‘free-pricing’ system for drugs to onewhere
prices are influenced by governmental authorities. A product’s value will take into
account additional factors, such as wider societal benefits and therapeutic innova-
tion. The aim of this research is to determine the impact of comparative effective-
ness and VBP on the price and market access of new drugs in depression.
METHODS:A literature reviewwas conducted using electronic databases (Medline,
Embase, Google Scholar). The search was performed for the years 2009-2011 and
key terms included comparative effectiveness USA, value based pricing UK, drug
value and societal benefits. In addition, an analysis of a UK Department of Health
consultation paper and the US Agency for Healthcare Research and Quality policy
documents was performed in order to determine how comparative effectiveness
and VBP may affect the market access and commercial viability of products in
disease area of depression (SSRIs, SNRIs and atypical antidepressants). A spread-
sheet was used to capture data and a comparison was undertaken to compare and
contrast the twomarkets and the different implications. RESULTS: The addition of
comparative effectiveness and VBP are to take account of indirect costs associated
with all disease areas. Depression has high indirect associated costs associated
and, as such, the value of novel antidepressants will increase. This is likely to
enable better access to new products. CONCLUSIONS: The move to comparative
effectiveness and VBP is likely to change the market access of products, particu-
larly in certain disease areas. There will be more positive drivers for investment in
the disease area of depression. Moreover, decisions taken at themargin during the
drug development processwill be impacted as any change inmarket access is likely
to affect the ‘Go/No go’ decision criteria.
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OBJECTIVES: Many factors influence pharmaceutical reimbursement decisions.
This study aims to determine the influence of factors considered in the evaluation
of pharmaceuticals on the reimbursement decisions of government funded bodies
in OECD countries. METHODS: A search of MEDLINE, EMBASE, EconLit, Health Man-
agement Information Consortium, NHS EED and REPEC Economic working papers until
July 2010 was conducted. A hand search of the International Journal of Technology
Assessment in Health Care was undertaken (1990-2010). The following study de-
signs were eligible: experimental, quasi-experimental, retrospective, prospective,
case series and surveys or questionnaires design. The influential factors were re-
viewed across and within OECD countries. RESULTS: The search identified 12
quantitative studies and 23 qualitative studies. The quantitative studies consid-
ered the correlation between factors and decisions either through regression anal-
ysis of retrospective decisions or discrete choice experiments. Cost-effectiveness
was found to be consistently influential for reimbursement decision-making in
Australia, England, Canada and The Netherlands. There was variation in the defi-
nition of clinical considerations and other factors in studies conducted in coun-
tries. This limited comparability within and across countries. Studies reported
mixed evidence of the influence of the quality, quantity and type of clinical evi-
dence, robustness of economic models, sensitivity analysis, budget impact, lack of
alternative therapy and severity of disease on reimbursement decisions. Qualita-
tive studies reported narrative descriptions, case studies and interviews with de-
cision-makers. These studies supported the influence of cost-effectiveness found
in the quantitative evidence. They additionally described the influence of the com-
position of the decision panel, committee deliberations, stakeholder involvement
and lobbying on decisions. CONCLUSIONS: There is limited evidence on the influ-
ence of evaluation factors on reimbursement decisions in a few OECD countries
with established reimbursement processes. Wider investigation of the factors in-
fluential in other countries would allow comparison of the similarities and differ-
ences across OECD countries.
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OBJECTIVES: In this paper we estimate the relationship between the financial im-
pact of a new drug on the health care system in Australia and the probability of the
drug being recommended for reimbursement by the Pharmaceutical Benefits Ad-
visory Committee (PBAC).METHODS: Data in the PBAC summary database regard-
ing drug-reimbursement decisions made between July 2005 and November 2009
were abstracted. Financial impact was categorized as A$0 or less, greater than A$0
up through A$10 million, and greater than A$10 million per year. Descriptive anal-
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